Methotrexate Administration in Pediatric Capizzi Protocol
The Capizzi methotrexate protocol uses escalating-dose methotrexate WITHOUT leucovorin rescue, combined with PEG-asparaginase, as demonstrated in the COG AALL0434 trial for T-cell acute lymphoblastic leukemia. 1
Key Protocol Features
The Capizzi regimen fundamentally differs from standard high-dose methotrexate protocols by intentionally omitting leucovorin rescue to maximize antileukemic effect. 1 This approach was directly compared to high-dose methotrexate with leucovorin rescue in the COG AALL0434 study, where the Capizzi arm (C-MTX) demonstrated superior outcomes with 5-year disease-free survival of 91.5% versus 85.3% for the HD-MTX arm (P=0.005). 1
Dosing and Administration
- Escalating-dose methotrexate is administered during the 8-week interim maintenance phase 1
- The regimen is combined with PEG-asparaginase as an essential component 1
- No leucovorin rescue is given - this is the defining characteristic that distinguishes Capizzi from conventional high-dose methotrexate protocols 1
Essential Supportive Care
Despite the absence of leucovorin rescue, aggressive supportive measures remain critical:
- Aggressive IV hydration at 125 mL/m²/hr (approximately 3 L/day) must be maintained 2, 3
- Urinary alkalinization to maintain urine pH ≥7.0 using sodium bicarbonate, continued until methotrexate levels fall below 0.05 micromolar 2, 3
- Daily monitoring of serum creatinine and methotrexate levels at minimum 2, 3
Critical Safety Considerations
The patient must have normal renal function and adequate blood counts before each dose - this is non-negotiable given the absence of leucovorin rescue. 1 Any renal dysfunction dramatically increases toxicity risk when leucovorin is withheld.
When Leucovorin IS Required
If delayed methotrexate elimination develops (elevated levels beyond expected timeframe) or renal dysfunction occurs, leucovorin rescue must be initiated immediately despite the protocol design:
- Start leucovorin 10-15 mg/m² every 6 hours until methotrexate level falls below 0.1 micromolar 2, 3
- Escalate leucovorin dosing based on methotrexate levels: 20-30 mg every 6 hours for levels >1 micromolar at 48 hours, up to 1 g continuous IV infusion for severe elevation 4
- Consider glucarpidase for life-threatening delayed elimination with renal dysfunction 5
Monitoring Schedule
- Serum creatinine and methotrexate levels daily during and after infusion 2, 3
- Monitor at least 4-6 days after dosing to detect delayed toxicity 1
- Complete blood count monitoring for bone marrow suppression, which occurs most commonly in the first 4-6 weeks 1
Common Pitfalls to Avoid
Do not reflexively give leucovorin - the Capizzi protocol's efficacy depends on withholding it in patients with normal elimination. 1 However, maintain a low threshold to initiate rescue if methotrexate levels remain elevated or renal function deteriorates. 5
Avoid nephrotoxic medications including NSAIDs and trimethoprim-sulfamethoxazole during treatment, as these impair methotrexate clearance and dramatically increase toxicity risk when leucovorin is withheld. 1
Ensure adequate hydration BEFORE starting methotrexate - waiting until toxicity develops is too late. 2, 5